Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 8, 2000

View Archived Issues

Boehringer Ingelheim seeks approval for combination hypertension treatments

3M Drug Delivery Systems Division provides new pain management platform

Aptosyn/Xeloda combination to be tested in breast and colorectal cancers

Cellegy to commence phase II trial of Anogesic as hemorrhoid treatment

PathoGenesis establishes Paris-based company to distribute TOBI in France

Clinical trials of Alzheimer's disease diagnostic test commence

Magainin begins phase II trial of squalamine in ovarian cancer

IDEC-152 enters clinical trials for treatment of allergic asthma

Enrollment in phase I study of Avant's CETP vaccine now complete

Antizol granted conditional priority review by Canadian authorities

Enzo achieves successful transduction of human cells using novel vector

New Sumitomo compounds inhibit cytokine and IgE production

Taisho synthesizes new series for CRF-related disorders

More news from CROI: AIDSVAX clinical results presented

Antiinfluenza sialic acid derivatives emerge from R&D at RIKEN

Gastric antisecretory agents from KRICT superior to omeprazole in vitro and in vivo

Nonpeptide inhibitors of VLA-4-dependent cell adhesion in the Pfizer pipeline

Group of selective SK channel blockers in early development at NeuroSearch

Antisense oligonucleotides targeting IL-15 designed at Hisamitsu

Antiasthmatic agent ME-3301 in clinical trials in Europe

North American Vaccine reports Hib vaccine results to FDA advisory panel

United Biomedical reports progress toward the development of a potential AIDS vaccine

Enbrel receives E.U. approval as treatment for rheumatoid arthritis

Roche announces limitations on availability of FUDR

Chinese investigators design novel antitumor agents

U.S. and Scottish scientists discover novel CCR3 antagonist that inhibits eosinophil migration

Termination of AHP-Warner-Lambert merger proposal confirmed

Methods of wound healing using amphipathic peptides from Demegen